{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:17:46Z","timestamp":1779236266493,"version":"3.51.4"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,9,8]]},"DOI":"10.1001\/jama.2020.15539","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T04:29:38Z","timestamp":1597379378000},"page":"943","source":"Crossref","is-referenced-by-count":11,"title":["An Inactivated Virus Candidate Vaccine to Prevent COVID-19"],"prefix":"10.1001","volume":"324","author":[{"given":"Mark J.","family":"Mulligan","sequence":"first","affiliation":[{"name":"NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"12","key":"jed200076r1","first-page":"241","article-title":"Ten great public health achievements: United States, 1900-1999.","volume":"48","author":"Centers for Disease Control and Prevention (CDC)","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"jed200076r2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1542\/peds.2013-0698","article-title":"Economic evaluation of the routine childhood immunization program in the United States, 2009.","volume":"133","author":"Zhou","year":"2014","journal-title":"Pediatrics"},{"issue":"10240","key":"jed200076r3","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"jed200076r4","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.","author":"Zhu","journal-title":"Lancet"},{"key":"jed200076r5","article-title":"Phase 1\/2 study of COVID-19 RNA vaccine BNT162b1 in adults.","author":"Mulligan","journal-title":"Nature"},{"key":"jed200076r6","article-title":"An mRNA vaccine against SARS-CoV-2: preliminary report.","author":"Jackson","journal-title":"N Engl J Med"},{"key":"jed200076r7","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial.","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"jed200076r10","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials.","author":"Xia","journal-title":"JAMA"},{"issue":"4","key":"jed200076r11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"12","key":"jed200076r12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jama.1967.03130250057008","article-title":"Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated measles virus vaccines.","volume":"202","author":"Fulginiti","year":"1967","journal-title":"JAMA"},{"issue":"6494","key":"jed200076r13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development.","volume":"368","author":"Graham","year":"2020","journal-title":"Science"},{"key":"jed200076r8","author":"Sahin","year":"2020"},{"key":"jed200076r9","unstructured":"Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19: guidance for industry. Published June 2020. Accessed August 10, 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/development-and-licensure-vaccines-prevent-covid-19"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2769609\/jama_mulligan_2020_ed_200076_1599242805.43785.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T15:05:53Z","timestamp":1599577553000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2769609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,9,8]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.15539","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,8]]}}}